Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter cross-sectional study of SERM treatment status in Chinese premenopausal breast cancer patients
ChiCTR-OPC-15006747Phase 4Completed
- Sponsor
- Chinese Anti-Cancer Association
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tamoxifen and toremifene in breast cancer (2 arms), sponsored by Chinese Anti-Cancer Association. Primary endpoints: Adherence, Disease-free survival and 2 more. Started Jan 2015; status: completed.
02
Drugs
tamoxifentoremifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OPC-15006747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006747.